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Statement of translational relevance 
Activated tumour-specific T-cells represent a powerful selective mechanism to control malignancy. 
Therapeutic vaccination provides a way to selectively amplify and arm tumour-specific T-cells that 
is scalable and thus suitable for treating large numbers of patients.  This phase I trial establishes the 
safety and immunogenicity of therapeutic vaccination against Epstein-Barr virus (EBV), which is 
resident in several human cancers totalling 200,000 cases each year worldwide. It pilots detailed 
functional dissection of the immune response to vaccination as a pharmacodynamic readout. As 
well as being of direct clinical relevance, the ability to readily characterise vaccine-induced T-cell 
responses against non-self tumour antigens makes EBV an ideal model system in which to explore 
novel immunotherapeutic strategies. Our trial therefore lays the groundwork for future large-scale 
efficacy trials of the vaccine and for trials testing a combinatorial approach to immunotherapy, for 
example using non antigen-specific immune checkpoint inhibitors with immunogenic vaccination 
against tumour antigens. 
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Abstract 
Purpose - Epstein-Barr virus (EBV) is associated with several cancers in which the tumour cells 
express EBV antigens EBNA1 and LMP2. A therapeutic vaccine comprising a recombinant vaccinia 
virus, MVA-EL, was designed to boost immunity to these tumour antigens.  A phase I trial was 
conducted to demonstrate the safety and immunogenicity of MVA-EL across a range of doses. 
Experimental Design - Sixteen patients in the United Kingdom (UK) with EBV-positive 
nasopharyngeal carcinoma (NPC), received three intradermal vaccinations of MVA-EL at 3-weekly 
intervals at dose levels between 5x107 and 5x108 plaque forming units (pfu). Blood samples were 
taken at screening, after each vaccine cycle and during the post-vaccination period. T-cell responses 
were measured using IFNγ ELISpot assays with overlapping EBNA1/LMP2 peptide mixes or HLA-
matched epitope peptides. Polychromatic flow cytometry was used to characterize functionally 
responsive T-cell populations.  
Results – Vaccination was generally well-tolerated.  Immunity increased after vaccination to at 
least one antigen in 8/14 patients (7/14, EBNA1; 6/14, LMP2), including recognition of epitopes 
that vary between EBV strains associated with different ethnic groups. Immunophenotypic analysis 
revealed that vaccination induced differentiation and functional diversification of responsive T-cell 
populations specific for EBNA1 and LMP2 within the CD4 and CD8 compartments respectively. 
Conclusions - MVA-EL is safe and immunogenic across diverse ethnicities and thus suitable for use 
in trials against different EBV-positive cancers globally as well as in South East Asia where NPC is 
most common. The highest dose (5x108 pfu) is recommended for investigation in current phase IB 
and II trials. 
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Introduction 
Approximately one fifth of human cancers are causally linked with infectious agents (1). Epstein-
Barr virus (EBV) is harboured as a life-long asymptomatic infection in most adults but has potent 
growth transforming capability (2). It is aetiologically linked to several human tumours, including 
undifferentiated nasopharyngeal carcinoma (NPC), an epithelial malignancy common throughout 
South-East Asia that also occurs at lower incidence rates worldwide (1,2). The possibility of 
exploiting EBV-specific T-cell immunity as a novel treatment for NPC is attractive because disease-
free survival rates at 2 and 5 years with current chemoradiotherapy regimens are still only 63% 
and 52%, respectively; furthermore, distant metastases account for over 40% of recurrences and 
confer a poor outlook (3–6). However, most NPCs express just two EBV latent cycle proteins: (i) the 
Epstein-Barr nuclear antigen 1 (EBNA1), a sequence-specific DNA binding protein involved in 
maintenance of the episomal virus genome; and (ii) latent membrane protein 2 (LMP2), a 
membrane signalling protein with growth-promoting activity in epithelial cells (2). In other EBV 
genome-positive tumours, such as all extranodal NK/T lymphomas (ENKTLs), up to 40% of 
Hodgkin lymphomas (HLs) and 5-10% of gastric carcinomas (GCs), EBNA1 and LMP2 are likewise 
among the limited range of expressed viral proteins, emphasizing the broader importance of these 
antigens as targets for immunotherapy (7–9). 
In light of these considerations, we developed a therapeutic vaccine (MVA-EL) using the modified 
vaccinia Ankara (MVA) vector to encode a functionally inactive fusion protein of full-length LMP2 
and the C-terminal half of EBNA1 (10). The latter region of EBNA1 contains almost all of the 
protein’s known CD4 and CD8 T-cell epitopes, but lacks the glycine-alanine repeat domain that 
partially impairs antigen presentation to CD8 T-cells (11–13). We recently reported the outcome of 
a phase I dose escalation trial conducted in a Hong Kong-based cohort of eighteen Chinese NPC 
patients vaccinated after initial chemoradiotherapy for their disease. In many cases, vaccination 
resulted in substantial expansions of circulating T-cells specific for EBNA1 and/or LMP2; moreover, 
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the numbers of responders and size of responses across the cohort both suggested a positive 
association with vaccine dose (14).   
Virus-induced T-cell responses are specifically directed against particular combinations of HLA 
molecules and bound viral peptides. Any global approach to T-cell-based targeting of virus-
associated tumours must therefore deal with the twin challenges of HLA diversity and viral 
heterogeneity. Differences between human populations in terms of HLA allele distribution will alter 
epitope selection (15–17), while polymorphisms between circulating viral strains can affect epitope 
processing and presentation (18–23). In this regard, the MVA-EL vaccine was constructed using 
EBNA1 and LMP2 gene sequences cloned from typical Chinese-origin EBV strains. These proteins 
differ from their European-origin EBV counterparts at various residues, some of which lie within 
known T-cell epitopes (15, 24). To what extent the vaccine would be able to boost epitope-specific 
responses in European patients therefore remained an open question.   
To address this issue, we undertook a dose escalation phase I trial of MVA-EL vaccination in the 
United Kingdom (UK).  Eligible patients with EBV-positive (EBV+) tumours were either in remission 
or harboured low volume residual disease for which no standard therapy was indicated. The 
objectives were to determine the safety profile and immunogenicity of MVA-EL vaccination and to 
assess changes in circulating cell-free EBV genome measurements over time. Here, we report that 
the vaccine was immunogenic and well tolerated in UK patients, potentially inducing the release of 
cell-free EBV genomes suggestive of tumour-specific T-cell-mediated cytotoxic effects. Combined 
data from 27 patients across both the Hong Kong and UK trials further confirmed the 
immunogenicity of MVA-EL across HLA subtypes and antigenic variants of EBV, supporting the use 
of this vaccine in different populations and thus potentially against a wider range of malignancies.   
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Methods 
Patients 
Sixteen patients with histologically confirmed EBV+ malignancy, either in first remission or with 
persisting disease for which no standard therapy was available, were recruited for this study. All 
patients were in complete (or unconfirmed complete) remission at least 12 weeks after first-line 
treatment (either definitive chemoradiotherapy or palliative chemotherapy) and met pre-defined 
inclusion criteria (see Supplementary Information). Conduct was ICH-GCP compliant and all 
patients gave written informed consent.  
 
Study design 
This was a three centre, phase IA trial of MVA-EL vaccination against EBV+ malignancies, employing 
a 3+3 design across a pre-defined dose escalation schedule of sequential cohorts spanning five dose 
levels (Supplementary Figure 1). The primary objectives were to determine the safety and toxicity 
profile of MVA-EL and to describe changes in EBNA1/LMP2-specific functional T-cell response 
frequencies in peripheral blood before, during and after vaccination. Additional objectives were to 
assess changes in EBV genome levels and EBNA1-specific antibodies in plasma. Disease response 
assessment was not an objective, but patients known to have residual or recurrent disease were 
assessed by cross-sectional imaging at screening and at week 14. Toxicity was graded and dose-
limiting toxicity (DLT) defined according to the National Cancer Institute Common Terminology 
Criteria for Adverse Events (CTCAE) v3.0 using a protocol-specific grading of local injection site 
reactions. Provided the maximum tolerated dose, i.e. the dose at which 2/6 patients suffered DLT, 
was not reached, the lowest dose for which there was clear evidence of cellular immunogenicity 
was to be recommended for further investigation.   
 
Study procedures 
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Patients received three intradermal vaccinations of MVA-EL at 3-weekly intervals. Blood samples 
were collected before vaccination (screening) immediately before each vaccination (day 1 cycle 1, 2 
or 3), 7 days after each vaccination (day 8, cycle 1, 2 or 3) and immediately post-trial (day 22 and 
day 29, cycle 3). Peripheral blood mononuclear cell (PBMC) and plasma samples were 
cryopreserved from each blood draw. T-cell responses were measured simultaneously for each 
individual patient across all time points via IFNγ ELISpot assays conducted against defined epitope 
peptides or pools of overlapping 15mer peptides spanning the primary sequence of each vaccine-
encoded antigen (pepmixes; JPT Peptide Technologies). Negative controls comprised DMSO solvent 
alone or an actin pepmix to assess spontaneous IFNγ release. Assignment of specific recognition 
required that the number of spot forming cells (sfc) observed in response to viral antigen 
stimulation exceeded defined thresholds, namely ≥10sfc/well and ≥2-fold greater than the negative 
control. Mean spot counts for negative control wells were subtracted from those for the test wells 
to generate mean adjusted readings. Vaccine responses were defined as peptide epitope or pepmix 
recognition for which the adjusted counts were ≥10sfc/well and ≥2-fold higher post-vaccination 
compared to pre-vaccination baseline.   
Antigen-specific T-cell phenotype was determined by stimulating PBMCs for 6hr with antigen 
pepmixes in the presence of brefeldin A, monensin and αCD107a-FITC antibody. Cells were then 
washed, stained with additional antibodies acquired on a custom-built 20-parameter FACS AriaII 
flow cytometer (BD Biosciences). Data were analysed with FlowJo software v9.7.5 and SPICE 
software v5.32 was used for combinatorial analysis and data presentation (25).  
EBV DNA loads in plasma were assayed by qPCR. EBNA1 antibodies were measured before and 
after vaccination using standard assays. PCR and sequencing were used to genotype EBV strains 
present in patients. Further details of procedures are provided in Supplementary Information. 
 
Statistical methods 
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Immunogenicity was not defined prospectively. Instead, interpretation of the immunological data 
was carried out in an exploratory manner using complete longitudinal data for each patient. Full 
details are provided in Supplementary Information.  
 
Regulatory status 
The trial was approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) in 
2004 (21106/0006/001 and 21106/0225/001) and by the UK Gene Therapy Advisory Committee 
(GTAC) in the same year (GTAC066). Sponsorship was provided by Cancer Research UK (Protocol 
PH1/101) and the trial was registered at clinicaltrials.gov (NCT01147991).   
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Results 
Patients, treatments and outcomes 
Sixteen patients with confirmed EBV+ NPC were enrolled from three UK clinical centres between 
2005 and 2010. The median age of this cohort was 48 years (range, 28-68 years). All patients had 
previously undergone either radical locoregional radiotherapy (n=4) or chemoradiotherapy 
(n=12), in ten cases with adjuvant chemotherapy (Table 1). Eleven patients were described as 
White and five as South East Asian. To genotype their resident EBV strains we PCR amplified a 
region of the viral genome used to discriminate between Chinese and European EBV strains (18,19) 
and that can be reliably amplified from the very low numbers of EBV-infected B cells present in 
small PBMC samples. Six EBV strain variants were identified in the eight patients who yielded an 
amplification product. The association between strain variants and ethnic origin (five White and 
three Asian) were consistent with previously described patterns (Table 1).  
Patients received three vaccinations at 3-weekly intervals in dose escalating cohorts as summarized 
in Supplementary Figure 1. Dose level 1 was expanded after the first patient on the trial 
experienced a grade 2 injection site reaction (ISR) to the first vaccine cycle. All participants 
experienced ISR at grade 1 or, in seven cases, at grade 2; these were non-ulcerative, self-limiting 
lesions that did not worsen across cycles. Nine patients experienced systemic toxicity, in five cases 
at grade 2 with regional pain and lymphadenopathy (2 patients), fatigue (1 patient) and ‘flu-like 
symptoms (3 patients). One of these patients (UK0212) withdrew from the trial after the first 
vaccine dose. 
At trial entry, ten patients were in complete remission following primary treatment or, for two 
patients, second-line therapy (UK0102, UK0516). Six had residual disease following primary 
treatment (UK0414) or more than one line of treatment (UK0103, UK0104, UK0105, UK0106, 
UK0313). Of these, plasma samples from four patients (UK0103, UK0104, UK0105, UK0313) 
contained detectable EBV DNA either before or 4 weeks after vaccination, triggering analysis of the 
complete sample set (Figure 1). For UK0105 and UK0313, sustained rises in EBV levels were 
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associated with disease progression. Patient UK0104 experienced increasing EBV loads before 
vaccination that appeared to stabilize initially, although relapse was clinically apparent 9 months 
after the first dose of MVA-EL. In UK0103, EBV load rose and fell transiently across the vaccination 
course and then stabilized at a lower level compared to baseline. Clinical relapse was diagnosed 25 
months after the first vaccination.   
 
Immune responses to vaccination 
Total lymphocyte counts remained stable across the vaccination course (pre-cycle 1, mean 0.94x109 
cells/L; week 11, mean 1.04x109/L). For most patients, CD3+CD4+ and CD3+CD8+ T-cell subset 
frequencies were typical of those in healthy controls; however, two patients showed atypical 
patterns that nonetheless also remained stable (Supplementary Figure 2A). The proportions of 
circulating CD4+Foxp3+ regulatory T-cells ranged within 3-10% of the total CD4+ T-cell 
compartment, comparable to values reported for healthy individuals (26). These frequencies did 
not change significantly with vaccination (Supplementary Figure 2B).     
To evaluate T-cell responses against known EBNA1 or LMP2 epitopes restricted by HLA class I or 
class II molecules, we tested PBMCs from sequential blood samples in IFNγ ELISpot assays. In 
particular, we looked for evidence of responses against polymorphic epitopes based on B95.8 type I 
EBV, which is prototypic for prevalent viral strains in Europe but differs at key epitopic sites 
compared to the equivalent MVA-EL sequences derived from Chinese strains (Supplementary Table 
1).   
Results from two patients are illustrated in Figure 2. For UK0102, candidate targets included the 
HLA-A*02.01-restricted CLG and FLY epitopes from LMP2 and the HLA-DRB1*0101-restricted TSLY 
epitope from EBNA1. The CLG and TSLY target peptides used in the assay varied compared to the 
vaccine-derived epitopes, whereas the FLY epitope was conserved. Weak pre-vaccination 
recognition was observed against CLG, but reactivity to all three epitopes increased after 
vaccination. In contrast, there was no corresponding increase in reactivity to a non-vaccine control 
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HLA-A*02.01-restricted epitope, GLC, derived from the immunodominant EBV lytic cycle protein 
BMLF1. For UK0310, candidate targets included the LMP2-derived epitopes, PYL and TYG, 
restricted by HLA-A*24. The PYL epitope is conserved between Chinese and European strains, 
whereas TYG differs at a single residue. For both targets, pre-existing T-cell recognition was 
amplified by MVA-EL vaccination.   
Overall, given the patients’ HLA types, 12 vaccine recipients could be screened for responses 
against potentially relevant EBNA1 or LMP2 epitopes (Supplementary Table 2). Epitope-specific 
responses were detected in 4/9 White patients tested. In addition to UK0102 and UK0310 
illustrated above, patients UK0105 and UK0209 (both HLA-A*02.01+) responded to the FLY 
epitope; UK0105 also responded to a second HLA-A*02.01-restricted LMP2 epitope (LLW) and an 
HLA class II-restricted EBNA1 epitope (VFLQ). These epitopes are all conserved between typical 
European EBV strains and the vaccine insert. Epitope-specific responses were also observed in 2/3 
South East Asian patients. In one case (UK0103), responses were directed against a pool of peptides 
containing two HLA class II-restricted EBNA1 peptides, each differing by one residue from the 
corresponding vaccine-expressed epitopes. Responses against CLG and LLW, as well as an HLA-
B*40-restricted LMP2 epitope (IED), were detected in UK0414. Again, the CLG and IED test 
peptides differed from the corresponding vaccine-encoded sequences.   
Next, we used surplus PBMCs from nine patients to examine T-cell responses against whole 
antigens, represented in pools of 15mer peptides with consecutive 10 residue overlaps (pepmixes) 
spanning the EBNA1 and LMP2 protein sequences derived from EBV strain B95.8. The self-antigen 
actin was used as a negative control for spontaneous IFNγ release. In addition, we included 
pepmixes for EBNA3A, an EBV latent protein not encoded by the vaccine, and influenza matrix and 
nucleoproteins (FLU). Recognition of these antigens was expected to be present in at least some 
patients and to fluctuate, but variations over time would not be predicted to have a consistent 
relationship to vaccination.     
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Longitudinal pepmix data from three patients are shown in Figure 3A. In each case, as in most NPC 
patients, pre-existing levels of EBNA1 and LMP2 recognition were low or even undetectable. 
Patient UK0101, who did not complete the vaccine course, nevertheless showed evidence of small 
EBNA1 and LMP2 responses 28 days after a single vaccine cycle, while the EBNA3A response 
remained static. Patient UK0207 showed an EBNA1 response as early as day 8 after the second 
vaccine cycle and an LMP2 response appeared after the third cycle, whereas control antigen 
responses again did not change. Patient UK0102 also mounted responses to both EBNA1 and LMP2, 
both of which were detectable after the second cycle and increased dramatically after the third. In 
this patient, FLU reactivity also increased markedly at the third time point. An increase in EBNA3A 
reactivity was observed in addition, although this increase was relatively small compared to 
baseline.  
Vaccination-induced changes in antigen reactivity are shown for all patients tested in Figure 3B. 
Pre-vaccination recognition of both vaccine and non-vaccine targets was commonly observed. 
Responses associated with vaccination, defined as ≥2-fold amplification and an increase of ≥10 
spots/well over baseline, were observed in 5/9 patients for EBNA1 and 3/9 patients for LMP2. In 
two patients, a 2-fold amplification was also detected for FLU but not for EBNA3A.   
Combining data from all ELISpot assays, using either defined epitope peptides or pepmixes as 
targets, there was evidence for low-level pre-vaccination recognition of EBNA1 and LMP2 in 11/15 
(73%) and 10/15 (66%) patients, respectively. Vaccination led to a >2-fold increase in EBNA1 and 
LMP2 reactivity in 7/14 (50%) and 6/14 (43%) patients, respectively. Overall, 8/14 patients 
responded to one or both vaccine antigens (Supplementary Table 2). There was no obvious 
relationship between variation in the resident EBV strain and vaccine immunogenicity. Responses 
were observed for UK0101, UK0102, UK0207, UK0310 and UK0414, who carried four different EBV 
strains based on virus genotyping analysis (Table 1 and Supplementary Table 2). A small increase 
in anti-EBNA1 antibody titres was also noted after vaccination (Supplementary Figure 3). 
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Multivariate analysis of immune function 
IFNγ ELISpot assays are sensitive but measure only a single T-cell function. To extend our analysis 
of vaccine immunogenicity, we selected one patient (UK0102) based on the presence of clear 
EBNA1/LMP2 responses and the availability of residual PBMCs to evaluate EBV-specific T-cell 
lineage, phenotype and function over the course of vaccination. PBMCs were stimulated with 
EBNA1, LMP2 or EBNA3A pepmixes and then co-stained for: (i) CD3, CD4 and CD8 (lineage); (ii) 
CD27 and CD45RO (phenotype); and (iii) IFNγ, IL-2, TNFα, MIP-1β and CD107a (function). The 
latter marker indicates degranulation and can act as a surrogate measure of cytotoxic activity (27).  
The chimeric protein encoded by MVA-EL contains a predominance of HLA class II-restricted 
epitopes in EBNA1 targeted by CD4 T-cells and HLA class I-restricted epitopes in LMP2 targeted by 
CD8 T-cells (Supplementary Table 1). We first asked whether vaccination amplifies both CD4 and 
CD8 T-cell responses detected with any of the five functional parameters. As predicted, the 
frequencies of EBNA1-specific CD4 T-cells and LMP2-specific CD8 T-cells increased with 
vaccination. Notably, the EBNA1-specific effectors were maintained at higher levels for more than a 
year, while the LMP2-specific response declined slowly over time (Figure 4A).  
Next, we asked whether vaccination also enhanced the quality of the T-cell response, determined as 
the number of effector functions elicited by antigen encounter. For this analysis, we compared data 
obtained from time points before and after three cycles of MVA-EL (Figure 4B). At the later time 
point, the frequencies of EBNA1-specific CD4 T-cells and LMP2-specific CD8 T-cells had increased 
by 120% and 420%, respectively. Moreover, for both vaccine-enhanced responses, the proportion 
of T-cells expressing only a single function decreased after MVA-EL administration, while the 
proportion of polyfunctional T-cells increased concomitantly. Pre-vaccination CD8 T-cell 
populations targeting the immunodominant EBNA3A protein were more polyfunctional compared 
to those specific for the subdominant LMP2 antigen, in line with previous reports (28, 29). 
However, there were no marked expansions of EBNA3A-specific CD8 T-cells after vaccination and 
no detectable shifts towards greater polyfunctionality. 
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Prior to vaccination, the majority of EBNA1-specific CD4 T-cells secreted TNFα alone or in 
combination with IL-2 or IFNγ; monofunctional MIP-1β-producing cells were also present. After 
vaccination, there was a substantial increase in polyfunctional CD4 T-cells secreting TNFα with 
IFNγ and/or IL-2. The proportion of single-function TNFα-producing cells decreased and the 
proportion of monofunctional MIP-1β-producing cells increased. The LMP2-specific CD8 T-cell 
population also contained a substantial proportion of monofunctional MIP-1β-producing cells that 
increased slightly after vaccination. Polyfunctionality was enhanced post-vaccination with more 
TNFα-producing cells making IFNγ in the presence or absence of MIP-1β, and a substantial increase 
in CD107a mobilization indicative of antigen-induced degranulation. 
Figures 4C and 4D show how these functionally distinct T-cells map onto the conventional 
partitioning of differentiation subsets defined by CD27 and CD45RO expression (30). The panels 
display antigen-reactive cells as pixels, colour-coded by function, overlaid on monochrome cloud 
plots showing the phenotypic distribution of all CD4 (for EBNA1) or CD8 (for LMP2 or EBNA3A) T-
cells. Effectors secreting MIP-1β were predominantly CD27loCD45ROlo both before and after 
vaccination, suggesting a state of terminal differentiation.  In contrast, EBNA1-specific CD4 T-cells 
secreting TNFα and/or IL-2 were predominantly CD45RO+, particularly after vaccination. Similarly, 
LMP2-specific CD8 T-cells secreting TNFα and/or IFNγ were strictly confined within the 
CD27+CD45RO+ compartment, most apparently after vaccination. Thus, in general, MVA-EL 
increased the frequency and functional diversity of effector T-cells without driving terminal 
differentiation. Nonetheless, highly differentiated CD107a+ LMP2-specific CD8 T-cells, likely 
representing potent cytotoxic effectors (31), were clearly present after vaccination.  
 
Data combination with the phase IA trial in Hong Kong 
The phase I trial described here and the parallel trial in Hong Kong (14) used the same vaccine 
batch, dose escalation scheme and ELISpot screening protocol, allowing us to explore the combined 
results. Table 2 shows the proportions of patients at each dose level with a >2-fold post-vaccination 
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increase in T-cells specific for each of the four antigens. Of the 27 patients for whom data were 
available, 18 and 12 responded to EBNA1 and LMP2, respectively. In contrast, only one and three 
patients showed increased responses to the non-vaccine target antigens, EBNA3A and FLU, 
respectively. Overall, 20/27 patients (74 %) showed increased T-cell responses to EBNA1 and/or 
LMP2; indeed, all patients vaccinated at dose level 3 or above responded to one or both of these 
vaccine-encoded antigens.  
Both trials also included response screening based on individual HLA-matched EBNA1 and LMP2 
epitope peptides; overall, 30 patients were analysed in this way. Figure 5A presents a linear map of 
the vaccine-encoded EBNA1/LMP2 antigen sequence depicting the position of all CD4 and CD8 T-
cell epitopes tested during the course of the two trials. Figure 5B identifies the epitopes against 
which a specific response was observed post-vaccination and the number of patients responding in 
each case. The vaccine was clearly immunogenic in the context of multiple HLA alleles. Thus, 
responses were induced against 9/15 HLA class I-restricted epitopes and 6/6 HLA class II-
restricted epitopes tested, with up to four patients responding per epitope.  
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Discussion 
EBV is found in the malignant cells of several different cancers and represents a rational target for 
therapeutic vaccination (2). NPC is a particularly common tumour among South-East Asian, 
especially Southern Chinese people, but occurs as a rare cancer in other populations (1,2).  
Although MVA-EL was designed to treat NPC (10), the vaccine’s clinical utility could potentially 
extend to other EBV+ malignancies such as ENKTL, HL and GC that similarly express EBNA1 and 
LMP2. These malignancies occur worldwide and variation in human populations and viral strains 
could therefore potentially affect their immune control.  To identify if the vaccine had broad 
applicability it was important to conduct a Phase I trial of similar design to that conducted in Hong 
Kong (14) but in a different population group. Here we present the results of this trial, performed in 
parallel with the Hong Kong study and of similar design but performed in NPC patients in the UK. Of 
the 16 patients vaccinated in the UK, 11 were of unspecified European origin, termed White, and 5 
were of South East Asian descent. 
Sequence variation is a feature of prevalent EBV strains across different populations and some 
polymorphisms can affect viral epitope presentation (18–23). In the present cohort of 16 patients, 
we were able to genotype the resident EBV strain in eight cases. Natural strain variation was 
detected consistent with previously described patterns in White and Chinese individuals (19). 
There were five genotypes in addition to the prototypic European strain, B95.8. This is relevant 
because the synthetic peptides used in our screening assays were based on B95.8 sequences. It 
therefore seems likely that strain-specific variation in individual EBNA1/LMP2 epitope sequences 
was present as described previously (17, 24). Importantly, such variation did not prevent the 
Chinese-origin LMP2 sequence encoded by MVA-EL from expanding T-cell populations originally 
generated by diverse viral strains.   
Substantial HLA diversity also exists between different populations, both in terms of the prevalent 
alleles (32) and allelic subtypes that can impact epitope selection (24). For example, although HLA-
A2 was the single most common allele in both UK (50%) and Hong Kong (78%) trial patients, 7/8 
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UK patients carried the HLA-A*02.01 subtype compared to only 1/14 patients in Hong Kong (14). 
Importantly, we found that vaccination increased the frequencies of several HLA-A*02.01-restricted 
LMP2-specific T-cell responses. Given the high frequency of HLA-A*02.01 in Western populations, 
this result is encouraging for worldwide deployment of the MVA-EL vaccine.  
Combining ELISpot data from the Hong Kong and UK trials of MVA-EL showed that vaccination 
increased T-cell responses to EBNA1 and/or LMP2 in 20/27 patients. Although the response rate in 
UK patients (8/14) was lower compared to the Hong Kong cohort (15/18), the UK data does not 
include any patients treated at the highest vaccine dose and, due to the expansion of the first dose 
cohort, includes six patients treated at the lowest dose. As MVA-EL immunogenicity increases with 
dosage (14), the UK response rate is likely to be an underestimate of what will be achieved in future 
trials using the highest, most immunogenic, dose.  
Many vaccine trials involving tumour-associated antigens of cellular origin are dealing with very 
low abundance reactivities and their analysis requires in vitro expansion, which may lead to 
phenotypic perturbations. In contrast, even though EBNA1 and LMP2 are generally subdominant 
EBV antigens, the size of these T-cell responses after vaccination may be sufficient to allow direct ex 
vivo analysis. This was the case with one of our vaccine recipients, UK0102, from whom additional 
blood samples were available to permit a more detailed characterization of MVA-EL-induced T-cell 
populations.  
Polychromatic flow cytometry revealed the true size and breadth of the immune response in 
patient UK0102, which was much larger than that measured by IFNγ ELISpot alone. Summing all 
five effector functions (IFNγ, IL-2, TNFα, MIP-1β and CD107a), the CD4 T-cell response to EBNA1 
reached over 0.2% of all CD4 T-cells in the blood. Similarly, the CD8 T-cell response to LMP2 
reached over 0.6% of all peripheral CD8 T-cells, a response of similar magnitude to that seen 
against EBNA3A, an immunodominant EBV antigen. Furthermore, different functional profiles were 
detected within these responses, such that vaccination increased not only the total numbers of 
EBNA1/LMP2-reactive T-cells, but also the proportion of those expanded populations with 
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polyfunctional capabilities. To some extent, the different functional subsets were linked with cell 
phenotype. In particular, MIP-1β-producing cells were typically separate from cells with other 
functional outputs and segregated within a highly differentiated (CD27loCD45ROlo) subpopulation. 
Importantly, MVA-EL vaccination did not appear to drive other functionally responsive cells into 
this terminally differentiated compartment, potentially enabling more durable immune memory. 
However, these results were obtained from a single patient and further work is needed to 
determine their broader significance. Multiplexed measurements enabled by polychromatic flow 
cytometry will therefore play an important role in the evaluation of vaccine-induced T-cell 
responses in our ongoing phase IB and II trials of MVA-EL.   
Other important factors determining widespread use of a therapy are its safety and tolerability. In 
the present trial, MVA-EL was generally well tolerated and 14 patients completed all three 
vaccination cycles at dose levels up to 5x108 pfu with reports of only grade 1 and 2 ISRs and 
systemic toxicities. The very first patient exhibited a florid ISR on cycle 1 (albeit grade 2) and a 
cautious approach led to an expansion of that dose level. On dose level 2, a patient withdrew 
following grade 2 ‘flu-like symptoms. Taken together with the Hong Kong data, the maximum 
tolerated dose has not been identified in the dose range tested, and the highest dose tested (5x108 
pfu) appears to give the most consistent immune response across both antigens. For these reasons, 
the recommended dose for further investigation is 5x108 pfu. 
The UK trial included 16 patients, all of whom underwent radiotherapy or chemoradiotherapy for 
NPC and, unlike the Hong Kong trial, six patients with residual disease at trial entry. Using plasma 
EBV DNA levels to demarcate tumour load and the risk of subsequent progression (33, 34), we 
noted two patients with apparent disease stabilization after vaccination (UK0103 and UK0104). In 
UK0103, we speculate that fluctuations in circulating EBV genome levels during vaccination might 
reflect T-cell-mediated cytotoxic activity against the tumour, as reported previously in the context 
of radiotherapy (35) and vaccination with MVA-EL (14). Patient UK0103 exhibited a response 
against a pool of HLA class II epitopes although cells were not available for testing with whole 
antigen pepmixes.  Patient UK0104 recognized both EBNA1 and LMP2 prior to vaccination, but no 
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amplifications were detected after MVA-EL administration. In two other patients, vaccination had 
no apparent clinical impact. Indeed, EBV levels rose relentlessly in one of these patients despite 
detectable immune responses to vaccination. Testing for a relationship between detectable immune 
reactivity and clinical benefit will require an expanded cohort of patients with residual disease 
consistently treated at the recommended dose. This trial is currently ongoing [ClinicalTrials.gov 
NCT01094405].    
As for extending MVA-EL to a wider range of malignancies, we note that several studies using 
adoptive T-cell transfer to boost EBNA1- or LMP2-specific effectors have reported clinical 
responses in patients with various EBV+ lymphomas (36–39). Using MVA-EL vaccination to boost 
the same T-cell responses may well lead to similar outcomes. The future of immunotherapy almost 
certainly lies in the development of rationally designed combination treatments. In this regard, the 
development of MVA-EL, with well characterised antigens and T-cell reactivities will allow us to 
investigate potential synergism between therapeutic vaccination and other modalities such as 
additive T-cell therapy, which has been applied to a range of EBV-associated malignancies including 
NPC (36-43), or immune checkpoint inhibitors such as anti-CTLA4 or anti-PD1 (44). 
In summary, the present trial provides three key advances. First, it provides further evidence of the 
safety and tolerability of MVA-EL, and supports the selection of dose level 5 for ongoing trials in 
NPC patients.  Second, it demonstrates the immunogenicity of MVA-EL across diverse ethnic 
backgrounds, thereby supporting proposals to trial this vaccine against other EBV+ cancers, 
including ENKTL, HL and GC. These malignancies occur worldwide in all ethnic groups and together 
cause a greater disease burden than NPC (45). Third, it demonstrates the potential importance of 
multiplexed functional and phenotypic measurements in the full characterization of vaccine-
induced T-cell responses. Collectively, these new data justify the ongoing development of MVA-EL 
through the next phase of trials with a view to eventual clinical use in the adjuvant setting to 
maintain remission following primary treatment or as treatment of relapsed disease, either alone 
or in combination with other modalities.  
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Figure Legends  
 
Figure 1. Time course of EBV DNA in plasma.  
Four patients had detectable EBV DNA in their pre-vaccination plasma. Following vaccination 
(indicated by arrows), EBV load increased transiently in one patient (UK0103) and then stabilized 
at a lower level compared to baseline. In a second patient (UK0104), a rising EBV load before 
vaccination appeared to stabilize after vaccination. Sustained increases in EBV load associated with 
disease progression were observed in two further patients (UK0105, UK0313). 
 
Figure 2 MVA-EL stimulates EBNA1 and LMP2 epitope-specific T-cell responses. 
Representative IFNγ ELISpot data from two patients showing the quantification of T-cell responses 
to defined EBNA1 or LMP2 epitope peptides. PBMCs from three different time points (pre-
vaccination, cycle 2 day 8 and cycle 3 day 8) were stimulated in parallel with the indicated epitope 
peptides at a cell input number of 300,000 PBMCs/well. Negative or positive control wells 
comprised the same number of PBMCs stimulated with DMSO solvent or phytohemagglutinin 
(PHA), respectively. Vaccine-encoded epitopes are highlighted in bold.  
 
Figure 3. Antigen-specific T-cell responses stimulated by MVA-EL.  
A. Representative IFNγ ELISpot data from three patients showing the quantification of T-cell 
responses to EBNA1 or LMP2 pepmixes. PBMCs from three different time points before and after 
vaccination as indicated were stimulated in triplicate with EBNA1 or LMP2 pepmixes at a cell input 
number of 300,000 PBMCs/well. Actin pepmix served as the negative control; EBNA3A and FLU 
pepmixes were included as additional controls. B. Graphs summarizing the results of whole antigen 
IFNγ ELISpot assays across nine patients. Spot-forming cells per well are shown for vaccine (left 
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panels) and non-vaccine (right panels) pepmixes, using samples taken before (filled boxes) and 
after (open bars) vaccination. Asterisks indicate increases in T-cell frequencies above the cut-off. 
 
Figure 4. Immunophenotypic analysis of T-cell responses in patient UK0102 before, during 
and after vaccination with MVA-EL.  
A. Graphs showing for patient UK0102 the total sizes of the indicated antigen-specific CD4 (left 
panel) and CD8 (right panel) T-cell responses before, during and after three cycles of vaccination 
with MVA-EL. PBMCs were stimulated with pepmixes and functionally responsive T-cells were 
enumerated by polychromatic flow cytometry on the basis of cytokine production (IFNγ, IL-2, MIP-
1β and TNFα) and surface mobilization of CD107a, a marker of degranulation. Combination gates 
were created with FlowJo software to determine the total magnitude of each response, counting 
each cell only once irrespective of discrete functional profiles. B. Functional profiles of antigen-
specific T-cells before (upper panels) and after (lower panels) three cycles of MVA-EL for patient 
UK0102. Pie charts display the numbers of functions expressed by EBNA1-specific CD4 T-cells 
(left), LMP2-specific CD8 T-cells (middle) and EBNA3A-specific CD8 T-cells (right) as indicated in 
the key. The outer arcs indicate the combinations of functions corresponding to each pie segment. 
The total size of the response is indicated in each case. C and D. Phenotypic profiles of functionally 
responsive CD4 and CD8 T-cells before and after vaccination for patient UK0102. The overall layout 
corresponds with panel B. The coloured dots depict functional antigen-specific T-cells, as indicated 
in the key, superimposed on cloud plots of the total CD4 and CD8 T-cell populations as appropriate.  
 
Figure 5. MVA-EL vaccination of NPC patients stimulates broad T-cell immunity specific for 
multiple epitopes in EBNA1 and LMP2.  
A. Diagram showing the design of the EBNA1/LMP2 fusion protein encoded by the MVA-EL vaccine. 
The location of defined epitopes used as peptide targets in IFNγ ELISpot assays are also indicated. 
HLA class I-restricted CD8 T cell epitopes are shown above the fusion protein; HLA class II-
restricted CD4 T-cell epitopes are shown below. B. Diagram showing the breadth of T-cell 
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responses stimulated by MVA-EL. Epitope location is represented by black (HLA class I) and white 
(HLA class II) lines on the fusion protein. Bar height above (HLA class I) and below (HLA class II) 
the fusion protein indicates the number of donors from the Hong Kong and UK phase IA trials that 
responded to the indicated epitope.  
 
 
 
Research. 
on January 28, 2015. © 2014 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 14, 2014; DOI: 10.1158/1078-0432.CCR-14-1122-T 
Table 1 Diagnosis, staging and previous treatment 
Trial 
no. 
Age Sex 
Ethn-
icity 
EBV 
geno-
type
1
 
Diag-
nosis 
Stage 
Tumour 
EBV 
status 
Radiotherapy Chemotherapy 
Weeks 
from last 
treatment 
Previous 
treatment 
outcomes 
0101 46 M White 
AVF/S1L2 
IVT/L2 
NPC T3N0M0 + 
1. 2003 nasopharynx: 66 Gy/33  +  cisplatin 
100mg/m(2) week 1, 3 and 6 [R] 
1. 2004 cisplatin 70 
mg/m(2) plus 5FU 
1000mg/m(2) d1-4 
q21/7, 2 cycles [R] 
91 1. CR 
0102 39 M White 
AVF/wt 
IVT/wt 
NPC T1N2M0 + 
1. 2004: external beam dose NK + cisplatin  [R]; 2. 2006: 
nasopharynx brachytherapy 60.1 Gy 
1. 2004: Cisplatin and 
5FU 
29 1. CR; 2. CR 
0103 28 F 
South 
Asian 
N.D. NPC T2N2cM0 + 
1. 2004: nasopharynx 65 Gy/30 + cisplatin [R]; 2.  2004: 
neck 60Gy/30 [R]; 3. 2004: vertebral column 20Gy/5 
[P] 
1. 2004: cisplatin and 
5FU; 2006: 4. cisplatin 
and 5FU 
12 
1. CR; 2. CR; 
3. PR; 4. PR 
0104 41 F White 
AVF/S1L2 
IVT/L2R9 
NPC 
Not 
Known 
+ 
1. 1999: nasopharynx, neck 64Gy/32 [R]; 2. 2004: 
nasopharynx brachytherapy 60Gy [R]; 3. 2005: right 
thyroid and neck 65Gy/30 + cisplatin then carboplatin 
[R]. 
 
73 
1. CR; 2. CR 
3. SD 
0105 48 F White N.D. NPC T1N1M0 + 
1. 1996 nasopharynx dose NK [R]; 2. 2004: nasopharynx 
brachytherapy 58.6Gy [R] 
3. 2006: cisplatin then 
carboplatin, + 5FU 
25 
1. CR; 2. PR; 
3. SD 
0106 49 F White N.D. NPC T3N1M1 + 
1. 2003: nasopharynx and neck 60Gy/30 [R]; 2. 2004: 
nasopharynx brachytherapy 42Gy [R]; 3. 2006: 
stereotactic right parapharyngeal 60Gy/30 [R] 
1. 2003: cisplatin and 
5FU [R] 
50 
1. not-
evaluable; 
2. CR; 3. SD 
0207 39 F 
South 
Asian 
AVF/S1L2 
IVT/N9 
NPC T3N2bM0 + 1.2006: nasopharynx and neck, dose NK 1. 2006: NK [R] 83  1.CR 
0208 55 M White 
AVF/wt 
IVT/L2 
NPC T2bN1M0 + 
1. 2008: nasopharynx 66Gy/33 + carboplatin 100 mg on 
weeks 1-5 [R]  
28 1. CR 
0209 43 F White N.D. NPC T1N0M0 LMP1 IHC + 1. 2007: nasopharynx 65Gy/30 + carboplatin [R] 1. 2007: cisplatin + 5FU 
 
1. CR 
0310 68 M White 
AVF/wt 
IVT/wt 
NPC T2bN1M0 EBER ISH + 1. 2008: nasopharynx 66 Gy/33 + cisplatin [R] 
 
28 1. CR 
0311 59 M White N.D. NPC T3 N2 EBER ISH + 
1. 2008: nasopharynx and neck 40Gy/25 and 26Gy/13 + 
cisplatin [R] 
1. 2008: cisplatin then 
carboplatin, +5FU 
18 1. CR 
0212 63 M White N.D. NPC T2 N0 M0 EBER ISH + 1. 2008: nasopharynx 65Gy/30 + 5FU then cisplatin [R] 
 
29 1. CR 
0313 49 M 
South 
Asian 
N.D. NPC T4 N3 N0 EBER ISH + 2. 2007: nasopharynx and neck 66Gy/33 + cisplatin [R] 1. 2007: cisplatin + 5FU 69  
1.not 
evaluable 
2.PR 
0414 49 M 
South 
Asian 
AVF/P1 
IVT/L2 
NPC T3 N0 M0 EBER ISH + 1. 2008: nasopharynx and neck 60Gy/33 + cisplatin [R] 
1. 2008: cisplatin + 5FU 
[R] 
17 1. PR 
0415 38 M White N.D. NPC T2 N2 M0 EBER ISH + 1. 2008: neck and nasopharynx 66Gy/33 + cisplatin [R] 
 
68 1. CR 
0516 52 M 
South 
Asian 
AVF/S1L2 
IVT/N9 
NPC T2N2M0 EBER ISH + 2. 2009: neck & nasopharynx 70Gy/33 + cisplatin [R] 
1. 2009: docetaxol + 
cisplatin + 5FU [R] 
24  
1.not 
evaluable 
2. CR 
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 1 EBV genotypes as defined in (Midgley et al. J. Virol. 2003, 77(21):11507-11516). wt indicates amino acid sequence is identical to B95.8 type 1 EBV 
reference sequence.  
[R] – radical intent; [P] – palliaive intent; CR – complete response; PR – partial response; SD – stable disease; NK – not known.  
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Table 2. Combined immunological response data from two Phase 1 clinical trials of MVA-EBNA1/LMP2  
 
 Vaccine target antigens Viral non-vaccine antigens 
 EBNA1 LMP2 EBNA3A FLU 
Dose level 1 3/8 3/8 0/8 1/8 
Dose level 2 2/5 1/5 0/5 0/5 
Dose level 3 4/4 1/4 0/4 0/4 
Dose level 4 3/4 2/4 0/4 1/4 
Dose level 5 6/6 5/6 1/6 1/6 
All patients 18/27 12/27 1/27 3/27 
 
PBMCs were tested with the indicated antigen pepmixes in IFN ELISpot assays at one or two timepoints in a 
blood sample taken 28-77 days after receiving the first vaccine dose (cycle 2 day 8 and cycle 3 day 29). A T-cell 
response was defined as a >2-fold amplification of specific T cell frequency post-vaccination, using the mean of 
two readings if available and >10 sfc/well.  The proportion of patients who had a T cell response at each dose 
level is shown, as well as the total number of patients responding overall.  
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